Ampio Pharmaceuticals Announces Presentation at Imperial Capital 2012
Healthcare Investor Forum
GREENWOOD VILLAGE, Colo., April 16, 2012
GREENWOOD VILLAGE, Colo., April 16, 2012 /PRNewswire/ --Ampio
Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting
clinical trials on its three lead drugs (Ampion™, Optina^™ and Zertane^™),
licensing distribution of those drugs and engaged in further drug development,
announced Mike Macaluso, Chairman and Chief Executive Officer, and Dr. David
Bar-Or, Chief Scientific Officer, will present a company overview at the
Imperial Capital 2012 Healthcare Investor Forum, on April 17, 2012, at 11:00
a.m. Eastern time.
A webcast will be available via the Investors tab at the Ampio's website,
www.ampiopharma.com, and an archived version will be available on the
Company's website for 30 days following the presentation.
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for
inflammation, eye disease, kidney disease, CNS disease, metabolic disease and
male sexual dysfunction. The product pipeline includes new uses for previously
approved drugs and new molecular entities ("NMEs"). By concentrating on
development of new uses for previously approved drugs, approval timelines,
costs and risk of clinical failure are reduced because these drugs have strong
potential to be safe and effective while their shorter development times can
significantly increase near term value. A key strategy includes actively
exploring partnership, licensing and other collaboration opportunities to
maximize Ampio's product development programs. For more information about
Ampio, please visit our website, www.ampiopharma.com.
Ampio's statements in this press release that are not historical fact and that
relate to future plans or events are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of words such as
"believe," "expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include risks associated with clinical trials,
expected results, regulatory approvals, successful commercialization and
marketing of Zertane™ and the combination drug in Korea, and changes in
business conditions and similar events. The risks and uncertainties involved
include those detailed from time to time in Ampio's filings with the
Securities and Exchange Commission, including Ampio's Annual Report on Form
10-K and Quarterly Reports on Form 10-Q.
Contact: Investor Relations Ampio Pharmaceuticals, Inc. 720-437-6500
SOURCE Ampio Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.